Phase I and II Studies with Lobaplatin
Cisplatin (Cis-diamminodichloro-platinum) (II) is widely used in cancer therapy. This agent has become the main component of regimens that cure patients with cancer of the testicle and produces high response rates in patients with small cell cancer of the lung, ovarian cancer, and bladder cancers (1–2). However, the toxicity is severe including intensive nausea and vomiting and renal toxicity. Furthermore, oto- and neurotoxicity (3) were observed especially during long term therapy. The side effects encouraged the development of analogues with a better therapeutic index. Cis-diamino-1,1-cyclobutane-dicarboxylato-platinum (Carboplatin) was selected from a large number of analogues developed by Harrap et al (4). In the clinic this compound demonstrated less emetic and no nephrotoxic effects. Myelosuppression, mainly thrombopenia, is the dose limiting toxicity of carboplatin. A cross resistance between Cisplatin and Carboplatin was shown in most tumor types. In bladder and testicular cancer Cisplatin has a higher activity than Carboplatin. In most other tumor types the spectrum of activity is similar (5).
KeywordsOvarian Cancer Bladder Cancer Esophageal Cancer Testicular Cancer Platinum Complex
Unable to display preview. Download preview PDF.
- 5.K.R. Harrap, M. Jones, C.R. Wilkinson, H.McD. Clink, S. Sparrow, B.C.V. Mitchley, S. Clarke and A. Veasey. Antitumor, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: “Cisplatin. Current status and new developments” A.W. Prestayko, S.T. Crooke and S.K. Carter eds Academic Press New York, London, Toronto, Sydney, San Francisco, 193 (1980)Google Scholar
- 8.H.H. Fiebig, D.P. Berger, W.A. Dengler, E. Wallbrecher, and B.R. Winterhalter. Combined in vitro/in vivo test procedure with human tumor xenografts. In: “Immunodeficient Mice in Oncology” H.H. Fiebig and D.P. Berger ed, Karger, Basel, Contrib Oncol 42:321 (1992).Google Scholar
- 9.A. Harstrick, C. Bokemeyer, M. Scharnofkse, G. Hapke, D. Reile, and HJ. Schmoll. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and-resistant human testicular, ovarian and gastric carcinoma cell lines. Cancer Chemoth and Pharmacol 33:43 (1993).CrossRefGoogle Scholar
- 10.Investigator’s Brochure Lobaplatin, ASTA Medica AG, Germany (1993).Google Scholar
- 14.J.A. Gietema, E.G.E. de Vries, D.T. Sleijfer, P.H.B. Willemse, H.J. Guchelaar, D.R.A. Uges, P. Aulenbacher, R. Voegeli, and N.H. Mulder. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer 67:396 (1993).CrossRefPubMedGoogle Scholar
- 15.J.A. Gietema, G.J. Veldhuis, H.J. Guchelaar, P.H.B. Willemse, D.R.A. Uges, A. Cats, B. Boonstra, W.T.A. van der Graaf, D.T. Sleijfer, E.G.E. de Vries, and N.H. Mulder. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. BJC 71:1302 (1995).CrossRefPubMedGoogle Scholar
- 16.H.J. Schmoll, C.H. Könne, E. Papageorgiou, S. Luft, A. Harstrick, P. Bachmann, P. Hilgard, and U. Schubert. Single agent lobaplatin is active in patients with oesophageal squamous cell carcinoma: A phase II evaluation. Proc ASCO 14:201 (1995).Google Scholar
- 17.M. Degardin, M. De Forni, B. Chevallier, P. Kerbrat, M.A. Lentz, M. David, and H. Roché. Phase II study of Lobaplatin in head and neck cancer (HNC). Abstract 8. NCI-EORTC Symposium: 126 (1994).Google Scholar
- 18.C. Manegold, H.H. Fiebig, U. Gatzemeier, I. von Pawel, W. Queiβer, P. Bachmann, L. Edler, and P. Drings. Phase II Study of Lobaplatin in patients with advanced non small cell lung cancer. Onkologie 16, supplement 1, 13 (1993)Google Scholar
- 19.H.H. Fiebig, I. von Pawel, U. Gatzemeier, C. Manegold, L. Edler, K. Burk, P. Bachmann, W. Berdel. Phase II study of the platinum complex lobaplatin in patients with extensive small cell lung cancer after previous chemotherapy. Onkologie 16, supplement 1, 14 (1993)Google Scholar